AbbVie and Allergan Aesthetics, an AbbVie company announced they will present 12 abstracts and two late-breaking presentations during the 2022 American Academy of Dermatology (AAD) Annual Meeting, March 25-29, in Boston. Data across AbbVie and Allergan's diversified portfolio of medical and aesthetic dermatology products underscore the companies' deep-rooted commitment to advancing science and striving to redefine the standards of patient care.

AbbVie will present new research on the efficacy, durability and safety of Rinvoq (upadacitinib) and Skyrizi (risankizumab-rzaa). Notable data will include a post-hoc analysis from the Heads Up study evaluating the degree and distribution of skin improvement from baseline with Rinvoq versus Dupixent (dupilumab) in adults with moderate to severe atopic dermatitis. Additionally, AbbVie will present an interim analysis from the LIMMitless open-label extension trial investigating continuous Skyrizi treatment beyond 4.5 years in adults with moderate to severe plaque psoriasis, as well as new real-world findings from the CorEvitas Psoriasis Registry, including patient-reported outcomes with Skyrizi in adults with moderate to severe plaque psoriasis.

"We look forward to presenting data at AAD that demonstrate our leadership in and commitment to advancing research across a myriad of dermatologic conditions," said Celine Goldberger, M.D., vice president, head of U.S. medical affairs, AbbVie. "Science is at the core of our work, helping us in our commitment to improve the care of patients with serious immune-mediated conditions now and for years to come."

Allergan Aesthetics has one of the most researched portfolios in the aesthetics industry and will spotlight a novel hydrating serum. Additionally, the company will share results from a multicenter and randomized controlled study evaluating the safety and effectiveness of hyaluronic acid (HA) injectable gel for restoring jawline definition as well as data on the effectiveness and safety of onabotulinumtoxinA for the treatment of masseter muscle prominence.

"Our research and development team is focused on driving innovation to provide the most comprehensive, science-based product offerings that will continue to help advance aesthetic medicine," said Darin Messina, senior vice president, Allergan Aesthetics R&D. "We are proud to share our learnings and engage with the larger medical community at AAD."